Close Menu

Pall

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year. 

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

Following completion of the merger with Pall, Danaher plans to split into two publicly traded companies. 

Proceeds from the notes offering will be used to pay a portion of the $13.8 billion cost of acquiring Pall.

Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.

NEW YORK (GenomeWeb News) – Pall today announced an exclusive distribution deal covering India between Pall India and Spinchrom Life Sciences, a division of Spinco Biotech.

Pall last week launched a PCR-based test for microorganisms that cause beer spoilage.

Pall said last week that its GeneDisc assays for Listeria have received performance tested methods certification from the AOAC Research Institute.

NEW YORK (GenomeWeb News) – Pall today said that it has signed an agreement to acquire protein analysis products firm ForteBio for an undisclosed sum.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.